Price
Financials
Standalone, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.22 | 5.42 | 3.05 | 8.61 | 3.15 | 4.24 | 2.42 | 1.58 | 1.63 | 30.70 | 12.45 |
| Expenses | 0.00 | 0.25 | 5.37 | 2.88 | 8.07 | 2.87 | 4.15 | 2.32 | 1.55 | 1.72 | 28.43 | 10.76 |
| Operating Profit | 0.00 | -0.03 | 0.05 | 0.17 | 0.54 | 0.28 | 0.09 | 0.10 | 0.03 | -0.09 | 2.27 | 1.69 |
| OPM % | -13.64% | 0.92% | 5.57% | 6.27% | 8.89% | 2.12% | 4.13% | 1.90% | -5.52% | 7.39% | 13.57% | |
| Other Income | 0.02 | 0.04 | 0.00 | 0.00 | 0.17 | 0.00 | 0.01 | 0.00 | 0.06 | 0.14 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.02 | 0.01 | 0.05 | 0.17 | 0.71 | 0.28 | 0.10 | 0.10 | 0.09 | 0.05 | 2.27 | 1.69 |
| Tax % | 0.00% | 0.00% | 20.00% | 23.53% | 14.08% | 25.00% | 30.00% | 20.00% | 22.22% | 20.00% | 27.75% | 26.04% |
| Net Profit | 0.01 | 0.00 | 0.04 | 0.12 | 0.61 | 0.21 | 0.07 | 0.07 | 0.07 | 0.04 | 1.64 | 1.25 |
| EPS in Rs | 0.00 | 0.00 | 0.00 | 0.01 | 0.04 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.11 | 0.09 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.02 | 1.57 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.17 | 5.79 | 19.05 | 36.32 | 46.36 |
| Expenses | 0.02 | 1.56 | 0.07 | 0.03 | 0.01 | 0.13 | 0.07 | 0.54 | 5.74 | 17.98 | 34.02 | 42.46 |
| Operating Profit | 0.00 | 0.01 | -0.07 | -0.03 | -0.01 | -0.12 | -0.05 | -0.37 | 0.05 | 1.07 | 2.30 | 3.90 |
| OPM % | 0.00% | 0.64% | -1,200.00% | -250.00% | -217.65% | 0.86% | 5.62% | 6.33% | 8.41% | |||
| Other Income | 2.30 | 0.00 | 0.05 | 0.02 | 0.01 | 0.01 | 0.05 | 0.43 | 0.06 | 0.18 | 0.20 | 0.20 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 2.30 | 0.01 | -0.02 | -0.01 | 0.00 | -0.11 | 0.00 | 0.06 | 0.11 | 1.25 | 2.50 | 4.10 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 16.67% | 18.18% | 19.20% | 27.60% | |||
| Net Profit | 2.30 | 0.01 | -0.02 | -0.01 | 0.00 | -0.11 | 0.00 | 0.04 | 0.08 | 1.02 | 1.81 | 3.00 |
| EPS in Rs | 0.47 | 0.00 | -0.00 | -0.00 | 0.00 | -0.02 | 0.00 | 0.01 | 0.01 | 0.07 | 0.12 | 0.20 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 112% | 415% | 498% | 152% | ||
| Compounded Profit Growth | % | 79% | 256% | 213% | ||
| Stock Price CAGR | % | % | 114% | 384% | ||
| Return on Equity | % | % | 12% | 17% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 11.29 | 14.63 | 14.63 |
| Reserves | -7.95 | -5.64 | -5.64 | -5.66 | -5.66 | -5.66 | -5.77 | -5.76 | -5.72 | -2.75 | -4.62 | -2.81 |
| Borrowings | 2.86 | 0.56 | 0.57 | 0.59 | 0.59 | 0.59 | 0.69 | 0.73 | 0.61 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.38 | 0.36 | 0.20 | 0.21 | 0.20 | 0.20 | 0.22 | 0.22 | 0.53 | 0.15 | 1.94 | 24.85 |
| Total Liabilities | 0.17 | 0.16 | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | 0.07 | 0.30 | 8.69 | 11.95 | 36.67 |
| Fixed Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.76 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.17 | 0.16 | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | 0.07 | 0.30 | 8.69 | 11.95 | 15.91 |
| Total Assets | 0.17 | 0.16 | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | 0.07 | 0.30 | 8.69 | 11.95 | 36.67 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | -0.11 | 0.00 | 0.05 | -6.03 | -3.52 | 21.22 |
| Cash from Investing Activity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.18 | -20.57 |
| Cash from Financing Activity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.00 | 0.00 | 8.88 | 0.45 | 0.00 |
| Net Cash Flow | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 2.86 | -2.89 | 0.65 |
| Free Cash Flow | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | -0.11 | 0.00 | 0.05 | -6.03 | -3.52 | 0.46 |
| CFO/OP | 0% | 14% | 0% | 0% | 92% | 0% | -16% | -12,020% | -307% | 953% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 187.86 | 137.57 | 63.81 | ||||
| Inventory Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 187.86 | 137.57 | 63.81 | ||||
| Working Capital Days | -8,395.00 | -106.94 | -17,520.00 | -9,490.00 | -1,545.88 | 354.91 | 137.76 | -140.29 | ||||
| ROCE % | 2.65% | 13.48% | 22.90% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 99.98% | 99.99% | 100.00% | 100.01% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.01% | 100.00% |
| No. of Shareholders | 6,633 | 6,775 | 6,712 | 6,698 | 6,627 | 6,773 | 7,303 | 7,303 | 8,151 | 7,826 | 7,853 | 8,038 |
Fundamentals
Market Cap₹ 142 Cr.
Current Price₹ 9.67
Stock P/E47.2
Book Value₹ 0.81
ROCE22.9 %
ROE16.6 %
Dividend Yield0.00 %
Face Value₹ 1.00
Compounded Sales Growth (TTM)152%
Compounded Profit Growth (TTM)213%
Standalone figures.
Valuation
Market capRs 134 Cr
Enterprise valueRs 134 Cr
P/E (TTM)44.83x
Price to book11.38x
Price to sales2.90x
EV / EBITDA32.63x
EV / EBIT32.63x
EV / sales2.89x
Price to cash flow6.34x
Earnings yield2.23%
P/E, 3-year average8.07x
P/B, 3-year average0.49x
P/E, 5-year average8.44x
P/B, 5-year average0.26x
Profitability
Operating margin (excl. other income)6.33%
Operating margin (incl. other income)6.88%
EBITDA margin8.84%
Pre-tax margin8.84%
Net profit margin6.47%
Net margin, latest quarter10.04%
ROE16.58%
ROCE22.90%
ROA7.45%
ROE, 3-year average9.89%
ROCE, 3-year average13.01%
ROA, 3-year average6.37%
ROE, 5-year average6.25%
ROCE, 5-year average13.01%
ROA, 5-year average10.18%
ROIC (approx.)26.65%
Tax rate27.60%
Other income / net worth1.69%
Growth
Sales growth (latest year)90.66%
Profit growth (latest year)77.45%
Sales CAGR, 3 years497.81%
Sales CAGR, 5 years415.26%
Profit CAGR, 3 years256.35%
Sales growth QoQ-59.45%
Profit growth QoQ-23.78%
Sales growth YoY (latest quarter)414.46%
Profit growth YoY (latest quarter)1685.71%
Per share
EPS (TTM)Rs 0.20
EPS (latest year)Rs 1.24
EPS (latest quarter)Rs 0.09
EPS, 3-year averageRs 0.67
EPS, 5-year averageRs 0.52
Book value per shareRs 0.81
Sales per shareRs 3.16
Cash flow per shareRs 1.45
Free cash flow per shareRs 0.03
Efficiency
Asset turnover0.99x
Debtor days64 days
Debtors turnover5.72x
Cash conversion cycle64 days
Working capital days-140 days
Leverage
Cash and bankRs 1 Cr
Net debtRs -1 Cr
Net debt / EBITDA-0.17x
Owners' fund to total sources32.23%
Cash flow
Cash from Operating Activity (latest year)Rs 21 Cr
Cash from Investing Activity (latest year)Rs -21 Cr
Net Cash Flow (latest year)Rs 1 Cr
Free cash flow (latest year)Rs 0 Cr
Cash from ops / profit, 5 years3.97x
Sales to cash flow1.71x
Statement figures
Net sales (TTM)Rs 46 Cr
Net sales (latest year)Rs 36 Cr
Sales (latest quarter)Rs 12 Cr
Operating profit excl. other income (latest year)Rs 2 Cr
Operating profit (latest quarter)Rs 2 Cr
Other income (TTM)Rs 0 Cr
EBITDA (TTM)Rs 4 Cr
PBDT (TTM)Rs 4 Cr
Profit before tax (TTM)Rs 4 Cr
Tax (latest year)Rs 1 Cr
Net profit (TTM)Rs 3 Cr
Net profit (latest year)Rs 2 Cr
Net profit (latest quarter)Rs 1 Cr
Cost of goods sold (latest year)Rs 34 Cr
Total expenditure (latest year)Rs 34 Cr
Total income (latest year)Rs 37 Cr
Share capitalRs 15 Cr
ReservesRs -3 Cr
Shareholders' fundsRs 12 Cr
Total assetsRs 37 Cr
Capital work in progressRs 21 Cr
ReceivablesRs 6 Cr
Other liabilitiesRs 25 Cr
Shares outstanding (crore)14.65
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 44.8 is at the 30th percentile of its own 2.5-year range
(median 120.7, low 29.9, high 376.2).
P/B 11.38 is at the 72th percentile (median 4.46).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | 524238 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -1.1% | -2.8% | +1.7 pts |
| 1 month | -24.6% | -6.8% | -17.8 pts |
| 3 months | -92.7% | -7.6% | -85.1 pts |
| 3 years | +836.7% | +14.2% | +822.6 pts |
Red flags
F-score 6 of 8No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹12 Cr +414.5% vs Jun 2025.
Net profit ₹1 Cr +1685.7%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Gujarat Inject (Kerala) Ltd?
Gujarat Inject (Kerala) Ltd (524238) has a market capitalisation of Rs 142 Cr. at the 2026-10-01 close.
What is the P/E ratio of Gujarat Inject (Kerala) Ltd?
Gujarat Inject (Kerala) Ltd trades at a P/E of 47.2 on trailing twelve-month profit, at the 2026-10-01 close.
What were Gujarat Inject (Kerala) Ltd's latest quarterly results?
In the Jun 2026 quarter, Gujarat Inject (Kerala) Ltd sales was Rs 12 Cr (+414.5% vs Jun 2025) and net profit was Rs 1 Cr.